STOCKHOLM, Nov. 7, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT)(Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in the following conferences:
CEO Renée Aguiar-Lucander will also be speaking on a panel on Day 2 of the FT Global Pharma & Biotech Summit, which is taking place in November 7 - 9 2023 in London, UK. The Panel `Exploring Options for Strategic Partnerships' will take place at 11:05am GMT on Wednesday 8 November.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
The information was sent for publication, through the agency of the contact persons set out above, on November 7, 2023, at 16:00 p.m. CET.
The following files are available for download:
Conferences Press Release ENG |
| Last Trade: | US$40.00 |
| Daily Volume: | 0 |
| Market Cap: | US$1.080B |
August 13, 2024 July 26, 2024 June 18, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
